Abstract 106P
Background
Regorafenib is an oral tyrosine kinase inhibitor, currently mainly used clinically for the treatment of metastatic colorectal cancer, especially in patients with colorectal cancer after standard treatment failure. The aim of this study is to analyze the impact of the prognostic nutritional index (PNI) on the safety and survival of metastatic colorectal cancer patients receiving third line or higher treatment with regorafenib.
Methods
A retrospective analysis was conducted on 87 patients with advanced colorectal cancer admitted to Zhejiang Cancer Hospital from 2018 to 2023, who received regorafenib treatment at or above the third line. The PNI value was calculated using formulas, and the optimal cut-off values of pre-treatment and post treatment PNI were determined based on the ROC curve. Kaplan Meier analysis and Log rank test were used to analyze the impact of PNI on survival after regorafenib treatment. Further Cox proportional hazards regression was used to determine the independent prognostic factors.
Results
After receiving treatment with regorafenib, 87 advanced colorectal patients underwent stratified analysis of test indicators based on PNI. It was found that high PNI values had a significant effect on lymphocytes, red blood cells, total protein, and albumin level, with higher values than those in the low PNI group. In the basic clinical information analysis, we found that the PNI has a positive effect on patient survival. Patients with high levels of PNI have a median OS of 747 days, significantly higher than those with low levels of PNI with a median OS of 281 days. PNI value is an independent prognostic factor for total survival (OS); The younger group of patients has a longer median OS of 411 days and a median PFS of 94 days, which is also an independent prognostic factor for OS and PFS.
Conclusions
This study indicates that the prognostic nutritional index has a significant impact on the safety and survival of patients with metastatic colorectal cancer receiving third line or higher treatment with regorafenib. Patients with high PNI levels have a longer survival period, improved survival rate, and relatively better prognosis after receiving regorafenib treatment.
Clinical trial identification
Editorial acknowledgement
This work was supported by the 1022 Talent Training Program of Zhejiang Cancer Hospital, Zhejiang Provincial National Science Foundation of China (No. LBY23H080003).
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.